Peyronie’s Disease Surgery: Considerations, Tips, and Pitfalls
William O. Brant, MD, FACS, FECSM, explores surgical approaches for Peyronie’s disease, focusing on penile curvature correction.
Read MoreSelect Page
Posted by William O. Brant, MD, FACS, FECSM | Apr 2025
William O. Brant, MD, FACS, FECSM, explores surgical approaches for Peyronie’s disease, focusing on penile curvature correction.
Read MorePosted by William O. Brant, MD, FACS, FECSM | Feb 2025
William O. Brant, MD, FACS, FECSM, explores the complexities of medical malpractice and its impact on physicians.
Read MorePosted by William O. Brant, MD, FACS, FECSM | Aug 2024
William O. Brant, MD, FACS, FECSM, Urologist at the Veterans Affairs Medical Center in Salt Lake City, Utah, presents an analysis of surgical approaches for Peyronie’s disease. With a focus on both shortening and lengthening procedures, Dr. Brant delves into the intricacies of various surgical techniques, providing a thorough examination of each method’s benefits and considerations. In his meticulous exploration, Dr. Brant begins by discussing the placation technique, a procedure aimed at addressing the excessive curvature caused by Peyronie’s disease. He elucidates the surgical process, highlighting its potential for restoring penile function and improving patient satisfaction. Furthermore, Dr. Brant explores the outcomes of placation, including changes in penile length and erectile function, enabling readers to grasp the potential benefits and limitations associated with this approach. Moving forward, the discussion expands to encompass plaque incision and excision techniques, which involve the precise removal of the fibrous plaque responsible for the curvature. Beyond the technical aspects, Dr. Brant also emphasizes the importance of personalized decision-making in the management of Peyronie’s disease. He discusses the significance of considering individual patient needs, taking into account factors such as disease severity, patient preferences, and overall health. The presentation encompasses an array of clinical scenarios and surgical techniques, showcasing Dr. Brant’s wealth of experience and expertise in the field. From the assessment of deformities to the exploration of different incision options, the presentation offers a comprehensive overview of the surgical approaches available for Peyronie’s disease.
Read MorePosted by William O. Brant, MD, FACS, FECSM | Aug 2024
William O. Brant, MD, FACS, FECSM discusses the cardiovascular and overall health benefits of regular bicycling. He highlights the positive effects on physical fitness, weight management, and mental health, noting how these factors contribute to improved sexual health and performance. The presentation emphasizes the role of aerobic exercise, such as cycling, in enhancing blood flow, which is crucial for erectile function.
Dr. Brant also addresses the concerns regarding the adverse effects of prolonged cycling on male genital health. Dr. Brant examines the anatomical and physiological mechanisms behind these concerns, focusing on the impact of sustained pressure on the perineal nerves and blood vessels.
The presentation includes an analysis of studies investigating the prevalence and severity of cycling-related genital issues. Dr. Brant discusses the role of bicycle design, saddle shape, and cycling posture in mitigating these risks.
Read MorePosted by Neeraj Agarwal, MD | Jul 2023
Dr. E. David Crawford and Dr. Neeraj Argawal, MD, FASCO, discuss the recent FDA approval of Enzalutamide combined with Talazoparib. In this discussion, they examine a Phase 3 trial comparing Enzalutamide and Talazoparib versus Enzalutamide alone on mCRPC patients.
The results of the trial yielded significant differences in the outcomes between the Enzalutamide and Talazoparib combination arm and the Enzalutamide-Only arm. 37% decrease in the risk of progression or death was observed in the combination arm of the trial. In patient populations with tumors containing HRR mutations, the risk of progression or death was decreased by 55%.
Following its recent FDA approval, Dr. Crawford and Dr. Argawal discuss the clinically appropriate populations for Enzalutamide and Talazoparib combination therapy, the process of diagnosis, and the limitations of the therapy. Dr. Argawal emphasizes the necessity of germline testing in identifying predispositions to mCRPC patients and their families.
Dr. Crawford and Dr. Argawal conclude by examining the time to PSA progression in the two trial arms. In the Enzalutamide-Only arm of the trial, average time to progression was 11 months, whereas time to progression in the Combination arm was 28 months. They recognize that the overall survival data is immature at this time, but recognize that short-term benefits of combination therapy for this patient population are significant across the board.
Read More